Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J.L. Heerspink, Elvino Barros, Mikhail Kosiborod et al.|European Heart Journal|2021Cited by 122
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J.L. Heerspink, Dánae Duana Ávila, David Z.I. Cherney et al.|Kidney International|2021Cited by 95